Kornimate/medical-research-clean huggingface dataset:
the effect of different types of progestin on sleeping of menopausal women

Conditions: Menopausal and Postmenopausal Disorders

Summary: investigators have found that sleeping disorder is an important problem in menopausal women. there have been papers reporting the effect of hormonal therapy on sleeping, but fews have reported the effect of different progestogens on sleeping quality. there is a need for more in-depth study and more conclusive evidence about the progestins which have the most beneficial effects on sleeping disorders in menopausal women. this study is going to collect the data from newly identified menopausal patients who are eligible for continuous estrogen-progestogen therapy for their climacteric treatment. the affects of the therapy will be monitored for 3 months.

new patients who are eligible for hormonal therapy will be selected. they will be allocated randomly into 2 different groups, each group being prescribed 1 of 2 regimens of hormonal therapy: * 17 beta estradiol 1mg/day plus oral micronized progesterone 100mg/day * 17 beta estradiol 1mg/day plus dydrogesterone 10mg/day patients will have their sleeping quality accessed using the pittsburgh sleep quality index(psqi) at their 1st visit and once a month for 3 months. the first and third psqi score will be analysed.

Eligibility criteria:
inclusion criteria: * new menopausal patients at maharaj nakorn chiang mai hospital * suitable for estrogen plus progesterone treatment exclusion criteria: * contraindication for hormone replacement therapy * recently used sleep enhancing medicine * recently used psychotic medicine

Keywords: sleeping quality menopause climacteric progestin dydrogesterone micronized progesterone
use of 852a in metastatic cutaneous melanoma.

Conditions: Melanoma; Unresectable Metatstatic Cutaneous Melanoma

Summary: pilot study to test the efficacy of 852a administered intravenously up to 3 times per week for 12 weeks in subjects with inoperable metastatic cutaneous melanoma.


Eligibility criteria:
inclusion criteria: * advanced melanoma not responding to 1st line chemotherapy * histological evidence of melanoma * measurable disease according to recist criteria * ecog performance status less than or equal to 2 * life expectancy 6 months or more * normal organ and bone marrow function as defined by hematological and serum chemistry limits * adequate contraception for females of childbearing potential exclusion criteria: * stage iv disease which has previously progressed during interferon treatment. * restriction of some therapies/medications for a certain timeframe prior to enrollment and during the study including: investigational drugs, high dose corticosteroids, immunotherapy, immunosuppressive medications, radiotherapy and drugs known to prolong qt interval and/or induce torsades de pointes * history of uncontrolled seizure disorders * uncontrolled coagulation disorders. * history or evidence of myocardial ischemia, congestive heart failure or arrythmias requiring treatment in the past 6 months * history of uncontrolled intercurrent or chronic illness * concurrent malignancies. * brain metastases. * hiv positive. * prolonged qtc interval * uncontrolled intercurrent or chronic illnesses. * pregnant or lactating women

Keywords: oncology melanoma
hyperbaric oxygen and manipulative therapies to regain function post stroke

Conditions: Stroke; Motor Dysfunction; Chronic Stroke; Ischemic Stroke

Summary: to study safety, feasibility and outcomes of combining osteopathic manipulative therapies with hyperbaric oxygen therapy in reducing the functional deficits in stroke survivors in subacute and chronic phases post ischemic stroke. to document the same as part of a pilot project in anticipation of further investigational studies.

the primary objective of this study is to show that hyperbaric oxygen therapy combined with osteopathic manipulative therapies improve outcomes in patients who have persistent neurological deficits after ischemic stroke compared to historical norms. the secondary objectives of this study is to demonstrate safety and feasibility of treating patients post stroke with hyperbaric oxygen and osteopathic therapies as well as determine improvements in multiple assessment scales of motor function, depression, activities of daily living(adl) and pain

Eligibility criteria:
inclusion criteria: 1. post ischemic stroke 2. patients aged 18-80 3. nihss \>5 4. mrs\>/=3, which connotes moderate disability requiring some help. 5. persistent significant motor dysfunction of at least one arm 6. subacute stroke patients (within three months from time of stroke) 7. chronic stroke patients (more than 6months from time of stroke) 8. patient must be able to understand instructions and verbalize discomfort 9. reliable attendance for daily (m-f) hbot treatment and 2x/week omt sessions for up to 6weeks exclusion criteria: 1. hemorrhagic stroke 2. prior functional disability mrs \>1 3. expressive or receptive aphasia 4. bedbound patients due to lifting limitations for hbot 5. history of severe, advanced emphysema with bullous disease 6. prior history of spontaneous pneumothorax or chest surgery 7. prior history of depression requiring medications 8. pregnancy 9. concomitant non-conventional rehab therapies including: acupuncture, botulinum toxin injections, massage therapy 10. significant claustrophobia
relationships between macular pigment optical density and lacquer cracks in high myopic patients.

Conditions: High Myopia

Summary: lutein ans zeaxanthin, carotenoids provided by dietary intake are mainly located in the macular area. its absorption peak at 460 nm may reduce photic damages. the macular pigment density can be evaluated by its optical density. reduced macular pigment level is a significant risk factor for age-macular degeneration. the nutritional intake can minimise the risk of age-macular degeneration.


Eligibility criteria:
inclusion criteria: * age \>18 years-old * high axial myopia \< -6 dioptries * presence or not of lacquer cracks in bruch's membrane in one or both eyes * patients with social security coverage exclusion criteria: * age \<18 years-old * amblyopia in the studied eye * prior ocular surgery * corneal disease or severe dry eye syndrome * other retinal disease: diabetic retinopathy, age-related macular degeneration, macular hole, epiretinal membrane central * extensive chorioretinal atrophy * allergy to tropicamide * pregnancy
coblation versus suction diathermy in pediatric adenoidectomy

Conditions: Adenoid Hypertrophy; Adenoidectomy; Coblation Adenoidectomy; Suction Daithermy

Summary: the goal of this clinical trial is to compare two surgical procedures in endoscopic adenoidectomy including coblation and suction diathermy . the main questions it aims to answer are: does the coblation device have less time, less pain, less postoperative crustation and bad odor, less intraoperative bleeding, and less recurrence? participants will: will undergo both procedures every day for 6 months visit the clinic once every 2 weeks for checkups and tests keep a diary of their symptoms


Eligibility criteria:
inclusion criteria: * all patients aged 2 to 18 years * patients who had isolated adenoid hypertrophy * patients' hemoglobin levels above 10 mg/dl exclusion criteria: * those with recent upper respiratory tract infections, evidence of bleeding disorders, serous otitis media, chronic tonsillitis * those advised against undergoing adenoidectomy after consulting a phoniatrist * patients with atrophic rhinitis those with nasal obstruction caused by other nasal or paranasal conditions such as inferior turbinate hypertrophy, choanal atresia, deviated nasal septum, antrochoanal polyps, and other causes of nasal obstruction in children.

Keywords: endoscopic adenoidectomy adenoid hypertrophy pediatric suction diathermy coblation
effects of an exercise program in women over 60 yr. with hfpef and sarcopenia on functional capacity and quality of life

Conditions: Heart Failure With Preserved Ejection Fraction (HFpEF); Sarcopenia; Women

Summary: this prospective study will randomize (1:1) women with heart failure with preserved ejection fraction (hfpef) and sarcopenia to receive standard management alone or a combined 12-week supervised exercise program (combining aerobic and strength exercise) carried out in a single centre. after randomization, patients will be clinically evaluated. the primary endpoint (peakvo2) will be assessed by cardiopulmonary exercise testing (cpet) at 12 weeks. women over 60 with hfpef, functional class nyha class ii-iii, and sarcopenia criteria will be enrolled. a sample size estimation \[alfa: 0.05, power: 80%, a 20% loss rate, and at least a delta change of mean peakvo2: +1.9 ml/kg/min (sd±2)\] of 40 patients (20 per arm) would be necessary to test our hypothesis.

heart failure with preserved ejection fraction (hfpef) is a highly prevalent clinical entity that predominantly affects women, whose incidence has increased in the last decade and has a complex and multifactorial pathophysiology. sarcopenia, a prevalent concurrent condition, appears to be associated with reduced muscle strength and reduced maximal functional capacity. supervised training programs in patients with heart failure with reduced ejection fraction and sarcopenia have improved functional capacity. however, the researchers do not have evidence about the effects of a supervised training program on patients with hfpef and sarcopenia, mainly when affecting women older than 60. this work aims to evaluate the effect of a 12-week supervised exercise program in patients with hfpef and sarcopenia on maximal functional capacity evaluated by peak oxygen consumption (peakvo2).

Eligibility criteria:
inclusion criteria: * patients diagnosed with heart failure with preserved ejection fraction according to 2021 esc guidelines for heart failure, with n-terminal pro-b-type natriuretic peptide (nt-probnp) \>125 pg/ml, inthe last month. * stable symptomatic heart failure patients (new york heart association functional class ii-iii) during the last month. * age ≥ 60 years old. * the participant is willing to give informed consent to participate in the study. * sarc-f score ≥4 points. exclusion criteria: * inability to perform a valid baseline cardiopulmonary exercise test. * cardiac pacemaker. * significant primary moderate-to-severe valve disease. * effort angina or signs of ischemia during cpet. * primary cardiomyopathies. * cardiac transplantation. * any other comorbidity with a life expectancy of less than one year.

Keywords: heart failure with preserved ejection fraction sarcopenia cardiovascular diseases heart diseases heart failure women
evaluating of new screening tool for arthritis* in psoriasis

Conditions: Psoriasis; Psoriatic Arthritis

Summary: this study evaluates a new screening tool for arthritis in psoriasis and compares its reliability with well-known screening tool (topas 2).

early diagnosis and treatment of psa may prevent destruction in joints.our aim is to create a simple and user friendly screening tool that can be used by dermatologists in out patient clinics. a question pool will be created from a review of the literature and expert opinions from a physicians experienced in rheumatology and dermatologists .psoriasis patients will answer these newly created questions. all patients will be examined by dermatology and also physical therapy and rehabilitation-rheumatology experts. the diagnosis of psoriatic arthritis (psa) will be made by caspar (classification criteria for psoriatic arthritis) criteria and asas (assessment of spondyloarthritis international society) criteria for spondyloarthritis. synchronously patients will be asked for to reply turkish version of well known questionary named topas 2. according to the results of collected data, statistically best matched questions will be selected for turkish population. also, the reliability of tupast (turkish psa screening tool) and topas 2 (toronto psoriatic arthritis screen ii) will be compared statistically.

Eligibility criteria:
inclusion criteria: * psoriasis confirmed by dermatologist exclusion criteria: * unable to consent and understand * known other rheumatological disease

Keywords: psoriasis psoriatic arthritis screening tool
percutaneous dilatation tracheostomy, broncoscopy, pro-seal laryngeal mask

Conditions: Tracheostomy Complication

Summary: in this study, our primary goal is to compare whether there is any difference in the complication of using pro-seal laryngeal mask or intubation tube in bronchoscopy-guided percutaneous dilation tracheostomy procedure. our secondary goal is to compare in terms of processing time.

following the approval of muğla sıtkı koçman university clinical research ethics committee, 61 cases over the age of 18 who were scheduled for elective percutaneous dilatation tracheostomy in intensive care units were included in the study. elective percutaneous dilatation tracheostomy cases were randomly divided into two groups. group 1 was determined as endotracheal tube and group 2 as pro-seal laryngeal mask group. in the endotracheal tube group, which is a conventional method, after entering the trachea with percutaneous technique, the intubation tube was removed before dilatation and percutaneous dilatation tracheostomy was performed with the seldinger method. in the pro-seal laryngeal mask group, the fiberoptic bronchoscope was advanced with a pro-seal laryngeal mask, and after the correct position was achieved, percutaneous dilatation tracheostomy was performed using the seldinger method. arterial blood pressure, oxygen saturation, heart rate, arterial blood gas, mechanical ventilation mode, positive end expiratory pressure and mean airway pressure values were recorded before and 30 minutes after the procedure. the time until the end of the procedure and complications were determined.

Eligibility criteria:
inclusion criteria:hospitalized in intensive care units of our hospital and planned for elective percutaneous dilatation tracheostomy were included in the study. - exclusion criteria: * history of cervical trauma, * high-pressure mechanical ventilation (inspiratory pressure above 40 cmh2o), * pulmonary edema, * acute respiratory distress

Keywords: percutan tracheostomy bronchoscopy pro-seal laryngeal mask
multimodal prehabilitation during chemotherapy in patients with colorectal liver metastases

Conditions: Prehabilitation; Neoadjuvant Therapy; Liver Metastases

Summary: liver resection is the only curative treatment for patients with colorectal liver metastases (crlm). most patients undergo chemotherapy (ct) before liver surgery. ct objectively decreases patient functional capacity. it has already been demonstrated that a structured training program carried out during the 4 weeks following ct, while the patient is waiting for liver resection, is able to return the functional capacity to baseline levels. despite this, multimodal prehabilitation programs (mpp) during preoperative ct have not been evaluated or implemented. the aim of this study is to investigate whether a 16-week mpp applied during and following ct in crlm patients will result in a significant increase in physical fitness when compared to those that undergo mpp only during the 4-weeks, between the end of ct and liver resection.

the primary aim of the study is to evaluate the effectiveness of a multimodal prehabilitation program (mpp) in crlm patients, which will be implemented right through the period of preoperative ct and during the 4-weeks of recovery before liver resection. mpp will consist of in-hospital high-moderate intensive exercise training, nutritional assessment and high-protein supplementation, smoking cessation, psychological support and comprehensive geriatric assessment. expected improvement in physical fitness will be measured by the difference in meters achieved in the six-minute walk test (6mwt) and will be compared with patients that will follow the mpp only during the 4-weeks before surgery, when preoperative ct has been finished. secondary aims include patient reported outcomes measures such as quality of life, postoperative complications, length of hospital stay, 30-day mortality and re-admissions. protocol feasibility will be evaluated by monitoring all interventions.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years * written informed consent obtained from subject to participate in the study. exclusion criteria: * age \<18 years * asa health class status iv-v * mental conditions or disabling orthopedic and neuromuscular disease that prevent physical exercise or may compromise adherence to the program * medical contraindication to perform exercise * inability to obtain informed consent
visual acuity and optical coherence tomography one year after peeling of epiretinal membranes

Conditions: Epiretinal Membrane

Summary: improvement in visual acuity and retinal anatomy one year after surgery is assessed and compared to data preoperative and 3 months after surgery

improvement in visual acuity and retinal anatomy (documented by optical coherence tomography) one year after surgery is assessed and compared to data preoperative and 3 months after surgery. improvements in retinal morphology are analysed by remission of optical coherence biomarkers after surgery. aim of the study is to examine possible improvements of surgical outcomes in the period up to the one year follow-up.

Eligibility criteria:
inclusion criteria: * vitrectomy with membrane peeling due to an epiretinal membrane exclusion criteria: * none
extension study of long-term safety and efficacy of myozyme in patients with pompe disease who were previously enrolled in genzyme sponsored enzyme replacement therapy (ert) studies

Conditions: Pompe Disease Infantile-Onset; Glycogen Storage Disease Type II

Summary: this extension study was to monitor the long-term safety and efficacy of rhgaa treatment in patients with infantile-onset pompe disease who were previously treated with rhgaa derived from the synpac cell line


Eligibility criteria:
inclusion criteria: * the patient was enrolled in protocol aglu-008-01, aglu-009-02, or aglu01502 * the patient's legal guardian(s) provided written informed consent prior to any study related procedures being performed * the patient and his/her guardian(s) were able to comply with the clinical protocol, which required extensive clinical evaluations for an extended period of time. exclusion criteria: * patients were excluded from this study if they did not meet the specific inclusion criteria, or if the patient experienced any unmanageable ae in protocol aglu-008-01, aglu-009-02, or aglu01502 (as determined and agreed upon by the principal investigator and genzyme corporation), due to synpac rhgaa therapy, that would preclude continuing therapy
safety and efficacy of oral ptk787 in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration (amd)

Conditions: Wet Age-Related Macular Degeneration

Summary: this study evaluates the tolerability and safety of 3 months treatment with ptk787 tablets given daily. it also explores the efficacy of the compound in patients with wet age-related macular edema. in cohort 1 verteporfin/pdt is the active control. the protocol was amended to reflect the current standard of care for amd. as a result, ranibizumab is the active control for cohort 2.


Eligibility criteria:
inclusion criteria * male ≥ 65 years old or female ≥ 50 years old, with aged related macular degeneration * patients with subfoveal choroidal neovascularization secondary to amd exclusion criteria * eye disease that may result in visual loss during the study * uncontrolled high blood pressure, despite chronic stable treatment: systolic ≥ 140 mmhg, diastolic ≥ 90 mmhg * chronic therapy with topical, local or systemic corticosteroids. * use of other investigational drugs within 30 days * pregnant or nursing (lactating) women. other protocol-defined inclusion/exclusion criteria may apply

Keywords: wet age-related macular degeneration ptk787
effectiveness of coconut oil pulling with clove oil, coconut oil pulling and fluoride mouthwash on streptococcus mutans count in children

Conditions: Dental Caries

Summary: this study aims to compare the effectiveness of coconut oil pulling with clove oil, coconut oil pulling alone, and fluoride mouthwash in reducing streptococcus mutans levels in children aged 6-12 years. participants will be randomly assigned to one of three groups: 1. coconut oil pulling with clove oil group - daily swishing with coconut oil mixed with clove oil. 2. coconut oil pulling group - daily swishing with coconut oil alone. 3. fluoride mouthwash group (control) - using fluoride mouthwash as per standard guidelines. the primary outcome is the reduction in streptococcus mutans count, assessed through microbiological analysis of saliva samples at baseline, immediately after intervention, and after 4 weeks. secondary outcomes include patient acceptability, adherence, and gingival health. this randomized controlled trial will provide insight into natural alternatives for oral health maintenance in children. study location: cairo university, faculty of dentistry. estimated study duration: may 2025 - january 2026.

this study is a three-arm, randomized controlled trial assessing the impact of coconut oil pulling with clove oil compared to coconut oil alone and fluoride mouthwash on streptococcus mutans reduction in children. participants will be recruited from the pediatric dentistry department at cairo university and randomly assigned using a 1:1:1 allocation ratio. saliva samples will be collected at three time points (baseline, immediately after intervention, and 4 weeks post-intervention) for microbiological analysis. the study will also evaluate secondary outcomes such as patient compliance (measured using the mmas-4 scale), acceptability (using a 5-point likert scale), and gingival health (assessed with the löe \& silness gingival index). the findings aim to determine whether natural oil-based methods can serve as effective, non-invasive alternatives to fluoride-based mouth rinses in pediatric populations.

Eligibility criteria:
inclusion criteria: * 1.children aged 6-12 years old. 2.both male and female participants. 3.patients in good general health condition with no systemic disease. 4.patients' first guardians must provide written informed consent to participate in the study exclusion criteria: * 1.patients who have recently received fluoride treatments (within the last 2 weeks). 2.patients with a history of recent antibiotic administration (within the last 2 weeks). 3.patients who have recently used antimicrobial mouth rinses in the last 12 hours or topical fluoride treatments.

Keywords: tooth decay streptococcus mutans oil pulling coconut oil clove oil fluoride mouthwash pediatric dentistry oral hygiene